Loading...
The Oman Healthcare Market size was valued at USD 5.10 billion in 2025 and is projected to grow from USD 5.31 billion in 2026 to USD 6.74 billion by 2032, exhibiting a CAGR of 4.05% during the forecast period, i.e., 2026-32.
The healthcare sector in Oman is undergoing a significant transformation as rising disease prevalence, expanding healthcare infrastructure, and growing investment in advanced medical technologies reshape healthcare delivery across the country.
Non-communicable diseases (NCDs) are a major driver of healthcare demand in Oman. According to the World Health Organization, conditions such as cardiovascular diseases, diabetes, cancer, and respiratory diseases account for 83% of deaths . In comparison, the Oman Ministry of Health reports that around 80% of deaths are linked to NCDs.
In addition to chronic diseases, Genetic disorders also contribute to healthcare demand in Oman. Sickle cell disease is among the most prevalent hereditary conditions, with 5.7–6% of the population carrying the gene and 0.2–0.46% affected , increasing the need for genetic screening, specialized diagnostics, and long-term treatment services.
According to the International Agency for Research on Cancer (GLOBOCAN), Oman recorded 13,006 five-year prevalent cancer cases, along with 4,045 new cases and 2,261 deaths, highlighting the country’s rising cancer burden and increasing demand for oncology services.
Healthcare infrastructure in Oman includes 92 hospitals and over 1,100 outpatient and primary healthcare centers . In 2023, the Oman Ministry of Health facilities performed 86,955+ surgeries. The system has 7,691 hospital beds, with a density of 14.9 beds per 10,000 population.
To further strengthen healthcare capacity, Oman is investing heavily in infrastructure expansion. The government is currently constructing 9 new hospitals that will add more than 1,660 beds nationwide. One of the largest projects is the 700-bed Sultan Qaboos Hospital in Salalah, which involves an investment of approximately USD 358.8 million and aims to improve access to specialized healthcare services in the southern region .
Alongside infrastructure expansion, Oman is also strengthening its pharmaceutical and medical manufacturing ecosystem. Government data indicates that the country currently hosts around 20 pharmaceutical and medical supply factories, including 7 pharmaceutical manufacturing plants, 2 raw-material facilities, and 11 medical supply production units .
Additional investment is also emerging within healthcare industrial zones. For instance, a USD 39 million pharmaceutical manufacturing facility is being developed in Khazaen Economic City to produce injectables, capsules, syrups, and topical medicines, supporting domestic drug production and supply chain resilience.
The government’s long-term healthcare development strategy is closely aligned with Oman Vision 2040, which focuses on building a modern and resilient healthcare system while encouraging private sector participation. Under this framework, the country aims to attract approximately USD 1.59 billion in healthcare investments by 2025, targeting hospital development, digital health platforms, and specialized treatment services.
Overall, the Oman healthcare market is positioned for steady growth as infrastructure expansion, rising chronic disease prevalence, and increasing investment in pharmaceutical manufacturing and medical technologies strengthen the national healthcare ecosystem. These structural developments are expected to enhance healthcare access, improve treatment capacity, and support the long-term evolution of the country’s healthcare sector.
| Category | Segments |
|---|---|
| By Healthcare Expenditure Type | (Public Healthcare Expenditure, Private Healthcare Expenditure, Out-of-Pocket Expenditure), |
| By Pharmaceutical Segment | (Prescription Drugs, Over-the-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologics & Biosimilars), |
| By Therapeutic Area | (Cardiovascular Diseases, Oncology, Diabetes, Respiratory Diseases, Neurology, Infectious Diseases, Others), |
| By Medical Device Type | (Diagnostic Imaging Devices, Patient Monitoring Devices, Surgical Equipment, In-vitro Diagnostics, Orthopedic Devices, Cardiovascular Devices, Others), |
| By Technology Type | (Artificial Intelligence in Healthcare, Telemedicine & Remote Monitoring, Electronic Health Records (EHR), Healthcare Analytics, Robotic Surgery, Wearables & Health Apps), |
| By Healthcare Workforce | (Physicians, Nurses, Dentists, Allied Health Professionals), |
| By Insurance Type | (Public Health Insurance, Private Health Insurance), |
| By Disease Category | (Chronic Diseases, Infectious Diseases, Mental Health Disorders), |
| By End User | (Hospitals, Clinics, Diagnostic Centers / Laboratories, Ambulatory Surgical Centers, Home Healthcare, Research Institutes, Pharmacies, Others) |
The rising prevalence of chronic and lifestyle diseases in Oman is increasing the demand for healthcare services. Urbanization, sedentary lifestyles, and dietary changes are driving metabolic and cardiovascular conditions, requiring long-term treatment, diagnostics, and continuous disease management.
One of the most critical public health challenges in Oman is the rising incidence of obesity and related metabolic disorders. National survey findings from the Oman Ministry of Health indicate that more than 60% of adults in the country are overweight or obese, while over 25% of the population is classified as obese . This growing obesity burden significantly increases the risk of other chronic diseases, including diabetes, cardiovascular disorders, and hypertension.
According to the 2025 National Survey of Non-Communicable Diseases, approximately 33% of adults in Oman suffer from hypertension, with the prevalence increasing to around 40% among individuals aged 35 years and older.
Similarly, metabolic disorders are becoming more widespread, as about one in seven adults (approximately 14%) experience high blood sugar levels, while more than 6,500 new diabetes cases are reported annually in the country .
In addition, dyslipidemia is another major concern, with around one-third of adults (about 33%) experiencing high cholesterol levels, and the prevalence rises to nearly 40% among people over 40 years of age.
The growing burden of obesity, hypertension, diabetes, and high cholesterol is significantly increasing demand for healthcare services, diagnostics, and chronic disease management in Oman. As these conditions continue to rise, healthcare infrastructure expansion and advanced treatment solutions will play a crucial role in supporting long-term market growth.
The healthcare sector in Oman is increasingly adopting advanced diagnostic technologies to improve early disease detection, treatment precision, and clinical efficiency. As part of national healthcare modernization efforts, hospitals are integrating high-precision imaging systems and minimally invasive diagnostic tools to strengthen the management of complex diseases such as cardiovascular disorders, cancer, and metabolic conditions.
Leading healthcare institutions are actively deploying innovative diagnostic solutions to support accurate and timely treatment. For instance, in 2024, Royal Hospital introduced Orbital Atherectomy technology and optical coherence tomography (OCT) imaging to enhance the diagnosis and treatment of complex coronary artery blockages. These technologies enable cardiologists to obtain high-resolution images of coronary arteries, allowing precise visualization of plaque buildup and arterial structures . As a result, physicians can perform targeted interventions such as angioplasty and stent placement with greater accuracy and improved clinical outcomes.
The growing integration of advanced diagnostic tools also supports the expansion of minimally invasive treatment approaches, which help reduce surgical risks and improve patient recovery times. This trend is particularly important as Oman faces a rising burden of chronic diseases that require early detection and long-term monitoring.
The increasing adoption of advanced diagnostic technologies is transforming healthcare delivery in Oman. Continued investments in precision imaging and modern diagnostic systems are expected to enhance treatment outcomes and support the long-term growth of the healthcare sector.
Download Free Sample - Drive growth with insights-get market analysis tailored to your business.
Home healthcare and remote patient monitoring (RPM) are emerging as important growth opportunities in the healthcare sector of Oman as the government accelerates digital health adoption and telemedicine integration.
The Oman Ministry of Health integrated telemedicine into the Al-Shifa health information system, enabling physicians to remotely access patient records, conduct virtual consultations, and monitor chronic diseases such as diabetes, hypertension, and cardiovascular conditions.
Adoption of remote healthcare services has expanded significantly in recent years. Government-linked healthcare reports indicate that over 1.2 million teleconsultations were conducted across Oman in 2024, representing approximately 67% growth compared with the previous year as hospitals and primary care facilities expanded virtual care services. The increasing use of RPM technologies, including wearable monitoring devices and connected digital health platforms, enables clinicians to track vital parameters such as blood pressure, heart rate, and glucose levels in real time. These systems have also improved healthcare outcomes, with remote monitoring programs contributing to nearly a 20% reduction in hospital readmissions in rural areas, demonstrating the effectiveness of home-based chronic disease management.
The rapid expansion of telemedicine platforms and digital monitoring systems is transforming healthcare delivery in Oman. As chronic disease management increasingly shifts toward home-based care models, demand for remote patient monitoring technologies and home healthcare services is expected to rise, supporting sustained market growth.
Regulatory complexities and high compliance costs remain a notable challenge for healthcare companies operating in Oman. The sector is strictly regulated by the Oman Ministry of Health, which requires healthcare providers, pharmaceutical companies, and medical device manufacturers to obtain multiple approvals before entering the market. These procedures include facility licensing, product registration, and regulatory clearances, which often involve extensive documentation and administrative reviews.
Under updated regulatory frameworks, healthcare operators must secure separate licenses for hospitals, clinics, pharmacies, and pharmaceutical manufacturing facilities. The fee for issuing or renewing a hospital license has been set at approximately USD 7,800, while licenses for pharmaceutical factories cost around USD 3,900. Such regulatory costs increase the financial burden for both domestic investors and foreign companies seeking to establish healthcare facilities or introduce medical products in the country.
In addition to licensing fees, compliance with regulatory standards related to safety, facility infrastructure, and operational approvals further increases operational complexity for market participants.
High licensing fees and complex regulatory procedures can slow market entry and increase operational costs for healthcare providers. As a result, these regulatory barriers may limit competition and delay the expansion of healthcare services and technologies in Oman.
Diabetes represents a significant public health challenge in Oman, with around 15% of the total patients, highlighting the substantial prevalence of the disease and its significant contribution to the country’s overall healthcare burden.
According to the International Diabetes Federation, diabetes prevalence in Oman reached 17% among adults aged 20–79 in 2024, representing about 412,300 patients. The increase is largely driven by obesity, sedentary lifestyles, urbanization, and an aging population.
Diabetes incidence in Oman is estimated at 8.3 new cases per 1,000 person-years, indicating a steady rise in diagnoses. The disease increases the risk of cardiovascular complications, kidney failure, neuropathy, and stroke. In 2024, about 625 deaths among adults aged 20–79 were directly attributed to diabetes, highlighting its growing clinical burden .
Multiple risk factors contribute to the high prevalence of diabetes in Oman. Research indicates that obesity alone accounts for around 56.7% of diabetes cases, while limited physical activity, unhealthy dietary patterns, and rapid urban development further exacerbate the risk among the adult population.
The treatment landscape for diabetes in Oman is primarily managed through the national healthcare system overseen by the Oman Ministry of Health. Standard treatment protocols typically begin with lifestyle interventions, including dietary regulation, increased physical activity, and weight management, particularly for patients with type 2 diabetes. When lifestyle measures are insufficient, pharmacological therapies such as oral antidiabetic medications, including metformin and sulfonylureas, are commonly prescribed, while insulin therapy is utilized for individuals with type 1 diabetes and advanced cases of type 2 diabetes.
In recent years, the country has also expanded the adoption of advanced diabetes management technologies. In 2024, under directives from Haitham bin Tarik, the Ministry of Health initiated the provision of electronic glucose monitoring sensors and insulin pumps for children with type 1 diabetes, enabling continuous glucose tracking and more effective disease management .
Overall, the rising prevalence of diabetes, combined with advancements in treatment technologies and government-led healthcare initiatives, is expected to drive continued demand for chronic disease management services across Oman’s healthcare system.
Cardiovascular diseases represent a significant public health challenge in Oman, with around 10% patients, highlighting the substantial prevalence of the disease and its significant contribution to the country’s overall healthcare burden.
According to risk assessments aligned with the World Health Organization framework, 12.9% of adults are classified as high cardiovascular risk and 19.1% as moderate risk, indicating widespread exposure to cardiovascular risk factors .
The incidence of cardiovascular diseases also reflects the growing healthcare burden. Research conducted within primary healthcare settings in Oman has estimated a cumulative incidence of approximately 1,360 cardiovascular cases per 100,000 people, indicating a steady rise in new diagnoses and increasing demand for cardiac care services.
Cardiovascular diseases are also a leading cause of mortality in the country. According to data from the World Heart Federation, around 4,618 deaths in Oman were attributed to cardiovascular conditions, with an age-standardized mortality rate of approximately 326 deaths per 100,000 population.
Multiple lifestyle and metabolic factors contribute to the high cardiovascular disease burden in Oman. The primary risk factors include hypertension, obesity, diabetes, dyslipidemia, and tobacco use. Hypertension remains one of the most prevalent risk factors, affecting approximately 48% of men and nearly 39% of women, significantly increasing the likelihood of coronary artery disease, stroke, and other cardiovascular complications .
The treatment landscape for cardiovascular diseases in Oman has strengthened considerably in recent years, supported by investments in specialized cardiac centers, advanced diagnostics, and interventional cardiology services. The Oman Ministry of Health operates tertiary healthcare facilities such as the National Heart Centre at Royal Hospital in Muscat, which functions as the country’s leading cardiac care hub. The center offers comprehensive cardiovascular services, including coronary angiography, cardiac catheterization, pacemaker implantation, and complex cardiac surgeries for coronary artery disease and structural heart conditions.
Since its establishment, the facility has performed more than 8,300 heart surgeries and over 30,000 cardiac catheterization procedures, demonstrating the significant expansion of specialized cardiovascular treatment capacity in Oman’s healthcare system .
